Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-12

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.


Scope

  • Event-driven sales forecasts for 2007-16 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
  • Country and market specific issues that will impact sales opportunities and market landscape, including key patent expiries and product launches.
  • Case studies assessing the blockbuster potential of Novartis's direct renin inhibitor, Tekturna, and the impact of ESC/ESH guideline reform in Europe.
  • Comprehensive analysis of the current antihypertensives pipeline, including a clinical and commercial assessment of all key emerging therapies.


    • Report Highlights
    The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.

    Cozaar's patent expiry in the US, has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.

    Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve international blockbuster status and Exforge will achieve sales of at least $800m, set back slightly by the premature expiry of Pfizer's Norvasc patent.


    Reasons to Purchase

  • Quantify the future size of the antihypertensives market and identify opportunities for new products.
  • Learn how recent European healthcare reforms and guideline updates will shape the antihypertensives market.
  • Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.

    • Table of Contents

    Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb antihypertensives patent classification cozaar generic expiry analysis india aliskiren diovan

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.